JP2006335708A - Blood flow improving composition, and food and drink, feed, medicinal supplement and medicine containing the same - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a blood flow improving composition widely usable for food and drink, feed, medicinal supplement, medicine and the like because of being high in safety and practicability in addition to having superior blood flow improving effect. <P>SOLUTION: The blood flow improving composition is characterised by containing at least one selected from the group consisting of amla fruit, amla fruit juice, an extract of the amla fruit and an extract of the amla fruit juice, as an effective component. Amla is a plant having a scientific name of Emblica officinale or Phyllanthus embilica, and thought to be originated from India. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a composition for improving blood flow containing Amler fruit, fruit juice, and the like, and foods and drinks, feeds, quasi drugs, and pharmaceuticals containing the composition.

  In recent years, aging, westernization of eating habits, lack of exercise, excessive stress, etc. are major causes of increasing cardiovascular diseases such as arteriosclerosis and cerebral infarction. In such circulatory system diseases, a decrease in blood flow in microvessels has been observed, and it has been pointed out in recent years that this may have various adverse effects on the living body. Further, in familiar places, the relationship between itching of the skin, fatigue, high blood pressure and the like and blood flow has been pointed out.

  In the human body, blood circulation plays an important role in supplying oxygen and nutrients, and removing carbon dioxide and other metabolic waste products. These two functions are indispensable for the activity and survival of tissue cells. In addition, biological defense functions and immune functions are functions that depend on this blood circulation. Thus, blood circulation is involved in many important biological functions. It has long been recognized that healthy blood circulation is essential for human health. There have also been many reports on the effects of food taken with daily meals on the heart and vascular system.

  As described above, a great deal of attention has been directed to the effects of food on blood circulation and the heart / vascular system, while the importance of blood fluidity has often been overlooked. The reason for this is that, firstly, blood is a “liquid” and it has been assumed that it has “high fluidity”. Second, it is difficult to measure blood fluidity unexpectedly. It was difficult. However, plasma, the “liquid” component of blood, is only about half of the blood component (volume), and the other half is cellular components (red blood cells, white blood cells, platelets; red blood cells mostly). Considering this, it is understood that blood is not always fluid.

  This blood fluidity loses balance due to various factors such as smoking, hypertension, hyperlipidemia, and diabetes. When the symptom progresses, a significant peripheral blood circulation disorder occurs and the tissue becomes abnormal. This also makes it easy to understand that maintaining blood fluidity is essential for health.

  The fact that blood whose half volume is a cellular component can move as if it is “liquid-like” is due to blood viscosity, leukocyte deformability and adhesion, platelet adhesion, and red blood cell deformability. In particular, it is largely due to the deformability of red blood cells. The definition of erythrocyte deformability is not necessarily unified, but it is understood that it is the resistance to erythrocyte shape change, or the mechanical adaptation that erythrocytes exhibit to take on new forms (blood rheology). Recent progress, Medical Review, Inc., 14-56, 1992).

  The effect of red blood cell deformability on blood fluidity is more directly important when the blood vessel is a capillary vessel. The diameter of the capillary is about 5 μm on average, although it varies depending on the tissue. On the other hand, the diameter of red blood cells (biconcave disk) is about 8 μm for humans. Therefore, it is clear that erythrocytes cannot pass through capillaries unless they are deformed. Therefore, the deformability of erythrocytes is the most important factor that affects the blood flow velocity or blood flow of capillaries, and it can be said that it is the basic mechanism of blood fluidity.

Attention is now being focused on the mechanism by which red blood cell deformability is maintained and how it is affected by environmental factors such as diet. Therefore, ingestion of foods and food ingredients that have an effect of improving blood flow is considered to be effective in preventing blood flow reduction, which is considered to be one of the causes of various diseases including cardiovascular diseases. It is thought that it can contribute to prevention and health promotion. In addition, many foods and food ingredients that have the potential to improve blood flow have been reported so far, and specific examples thereof include umeboshi, plum extract (see, for example, Patent Document 1), black vinegar ( For example, refer to Patent Document 1) and Tartary soba.
JP-A-11-228561

  By the way, even if a food or a food component that can be expected to have an improvement in blood flow is found, it cannot be widely applied to foods and the like if there is a problem in flavor or properties. Therefore, from the viewpoint of practicality, it is desirable that the flavor, properties, etc. have few difficulties. Furthermore, from the viewpoint of safety, it is desirable that there is no risk of inducing strong side effects even if a large amount is ingested.

  The present invention has been made in view of the above problems, and its purpose is to have excellent blood flow improvement effect, and because of its high safety and practicality, food and drink, feed, quasi drug, An object of the present invention is to provide a composition for improving blood flow that can be widely used for pharmaceuticals. Another object of the present invention is to provide a food / beverage product, a feed, a quasi-drug, and a pharmaceutical product containing the excellent blood flow improving composition.

  Therefore, the inventors of the present invention have studied and studied from various angles for the purpose of searching for blood flow improving components from various natural plants, and as a result, the blood flow improving effect excellent in the fruit and fruit juice of a plant called “Amler”. I discovered something new. Accordingly, the inventors of the present application have further developed this new knowledge and completed the following invention.

  That is, the invention described in claim 1 is characterized in that it contains at least one selected from the group consisting of Amler fruit, Amler fruit juice, Amler fruit extract and Amler fruit extract as an active ingredient. The gist is a composition for improving blood flow. Since this composition has an excellent effect of improving blood fluidity, it is possible to prevent the occurrence of blood circulation disorders and blood coagulation. Moreover, this composition is derived from a natural plant that has been ingested by humans over a long period of time, and even if it is ingested in large quantities, there is no risk of inducing strong side effects and it is highly safe. In addition, Amler has a sour taste, but there are few difficulties with respect to flavor, and there are also few difficulties with respect to properties. Therefore, the composition is highly practical and can be widely used in foods and drinks, feeds, quasi drugs, pharmaceuticals, and the like.

  The gist of the invention described in claim 2 is that, in claim 1, the extract is obtained by extracting at least one selected from the group consisting of Amler fruit and Amler fruit juice with a non-organic solvent. To do.

  The gist of the invention described in claim 3 is that, in claim 1 or 2, a fraction obtained by using an organic solvent of the extract is contained as the active ingredient.

  Invention of Claim 4 contains the fraction obtained by refine | purifying what decomposed | disassembled and processed the said extract with the enzyme in any one of Claim 1 thru | or 3 as said active ingredient This is the gist.

  The gist of the invention described in claim 5 is that, in claim 4, the enzyme is a hydrolase.

  The gist of the invention described in claim 6 is a food or drink comprising the composition for improving blood flow according to any one of claims 1 to 5.

  Invention of Claim 7 makes the summary the feed characterized by including the composition for blood-flow improvement of any one of Claims 1 thru | or 5.

  The gist of the invention described in claim 8 is a quasi-drug containing the composition for improving blood flow according to any one of claims 1 to 5.

  The gist of the invention described in claim 9 is a pharmaceutical product comprising the composition for improving blood flow according to any one of claims 1 to 5.

  The “blood flow improving effect” in the composition for improving blood flow of the present invention containing an ingredient derived from Amler as an active ingredient can be evaluated by, for example, a technique using the following blood vessel model. That is, blood is collected from an organism that has taken the composition for improving blood flow of the present invention at a predetermined time after ingestion, and this is used as test blood. On the other hand, blood collected before ingestion is used as control blood. These two kinds of blood are flowed at a difference of 20 cm in water column using MC-FAN (both manufactured by Hitachi Haramachi Electronics Co., Ltd.) in Bloody 6-7, which is a finely processed flow path of a blood vessel model. And, the time for each blood to pass through the flow path is obtained as a blood flow passage time, and the blood flow improvement can be evaluated by comparing the blood flow passage time of the test blood and the blood flow passage time of the control blood. it can. In this comparison, if the blood flow passage time of the test blood is shorter than the blood flow passage time of the control blood, it can be determined that blood flow improvement has been observed.

  Alternatively, blood flow improvement can be evaluated by determining and comparing the speed (blood flow speed) at which each blood passes through the flow path. In this comparison, if the blood flow velocity of the test blood is higher than the blood flow velocity of the control blood, it can be determined that blood flow improvement has been observed.

  For example, when the organism ingesting the composition for improving blood flow of the present invention is a human suffering from a blood circulation disorder, the blood flow is monitored by monitoring the blood flow passage time (or blood flow velocity) at regular intervals after the ingestion. The improvement can be confirmed, and thereby the symptom, the illness, etc. can be evaluated for the alleviation and improvement. In addition, when the organism ingesting the composition for improving blood flow of the present invention is a healthy human (healthy person) who does not suffer from a blood circulation disorder, the blood flow passage time (or blood flow velocity) is similarly determined. By monitoring, the prevention of symptoms, diseases and the like can be evaluated. In the prevention evaluation, it is preferable to target healthy persons over 30 years old, preferably over 50 years old who are not suffering from the above-mentioned symptoms and diseases but are likely to suffer in the future.

  Therefore, according to the invention described in claims 1 to 5, in addition to having an excellent blood flow improving effect, it is widely used in foods and drinks, feeds, quasi drugs, pharmaceuticals and the like because of its high safety and practicality. A possible blood flow improving composition can be provided.

  Moreover, according to invention of Claim 6 thru | or 9, the food-drinks, feed, quasi-drug, and pharmaceutical which contain said outstanding composition for blood flow improvement can be provided, respectively. For this reason, by improving the blood flow, it becomes possible to alleviate, ameliorate, or prevent the blood circulation disorder, and furthermore, it is possible to alleviate, ameliorate, or prevent the cardiovascular disease caused by the blood circulation disorder.

  Hereinafter, the composition for improving blood flow according to one embodiment of the present invention, and foods and drinks, feeds, quasi drugs, and pharmaceuticals containing the same will be described in detail.

  The “Amler” used in the composition for improving blood flow of the present invention is a plant having the scientific name of Emblica officinale or Philanthus embrica. Amler is a deciduous sub-tree that belongs to the genus Euphorbiaceae, and is distributed from India to the Malaysian region and southern China, and India is considered the origin. In addition, Amler has a unique name for each region or language, for example, citrus, oil sweets, satsuma mushrooms, embrick milobaran, armaraki, malach tree, malaka tree, indian gooseberry, aronra, amira. , Amiraki, Amira Cattra, Nerikai, Neruri, Tasha, Kayuraka, Kemuraka, Nakhon Pong and others.

  In the traditional Indian medicine "Ayurveda", Amler is listed as one of the three best fruits for preventing and treating all diseases. However, there has never been a concrete report regarding the fact that Amler has an effect of improving blood flow, and the present inventor has newly discovered this time after earnest research.

  The site of Amler used in the composition for improving blood flow is not particularly limited, but fruit is preferably used. The form of the Amler fruit is not particularly limited, and any of an immature fruit, a fully ripe fruit, a dried fruit and the like may be used. The use of fruit juice obtained by squeezing the fruit is also preferable. The form of the fruit juice is not particularly limited, and may be either liquid or powder. The merit of using fruit juice is that it can be used as it is because the content of the water-insoluble component is small, and the step of removing the component can be omitted.

  When using a product containing a water-insoluble component such as fresh fruit or dried fruit, it is preferable to perform extraction to remove the water-insoluble component in order to improve the blood flow improving effect.

  When using fresh fruits, after removing the seeds in advance, extraction is performed after adding water as necessary. In addition, in order to improve extraction efficiency, it is preferable to use what was crushed and homogenized with a mixer etc. as an extraction raw material. The same can be said basically for the case of using dried fruits, but in order to increase the extraction efficiency, it is preferable to grind the particles so as to have a particle size of 40 mesh or less. Fruit juice is also preferably used as an extraction raw material.

  The solvent and temperature conditions used for extraction are not particularly limited, and can be arbitrarily selected and set. As the extraction solvent, a non-organic solvent such as water, a base, or an acid, or an organic solvent such as a hydrophilic solvent or acetone can be selected. As the hydrophilic solvent, at least one selected from the group of lower alcohols consisting of methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol and butyl alcohol is preferable from the viewpoint of operability and extraction efficiency. However, extraction with a non-organic solvent is preferable rather than extraction with an organic solvent, and it is particularly preferable to select one of water, a base and an acid.

  When an acid or base is used as the extraction solvent, it is preferable to neutralize the extract. The salt produced by the neutralization reaction can be removed by a known method such as dialysis or gel filtration. However, when water is used as the extraction solvent, the neutralization reaction as described above is not necessary, and it is not necessary to remove the generated salt. Therefore, it is most preferable to use water from the viewpoint of reducing man-hours and cost.

  The acid used at this time is not particularly limited, and most acids can be used. However, from the viewpoint of easy availability and operability, the use of hydrochloric acid or sulfuric acid, or the combined use of hydrochloric acid and sulfuric acid is preferred.

  In addition, the base is not particularly limited, and most bases can be used. However, the use of sodium hydroxide or potassium hydroxide or the combined use of sodium hydroxide and potassium hydroxide is preferred from the viewpoint of availability and operability.

  The concentration of the acid or base used for the extraction is not particularly limited before or after the extract is treated with the enzyme. Although it varies depending on the strength of the acid or base, from the viewpoint of operability and extraction efficiency, it is preferable to use 0.01 to 0.5 molar acid or base.

  In the above extraction, it is preferable to use an enzyme treatment together, and this treatment can improve the yield and flavor, and can obtain a component having a high blood flow improvement effect. The enzyme treatment may be performed before extraction or at the time of extraction. The pH at which the enzyme treatment is performed can be appropriately set using the optimum pH and pH stability of the enzyme used as an index. Also, the temperature at which the enzyme treatment is performed can be appropriately set using the optimum temperature and temperature stability of the enzyme to be used as an index.

  The enzyme used for the enzyme treatment of the present invention is not particularly limited, but is preferably a hydrolase often used in the food industry. This is because this type of enzyme has been used and is preferable from the viewpoint of safety and the like. Specific examples of the enzyme include hydrolytic enzymes such as pectinase, amylase, protease, lipase, tannase, dextranase, cellulase, hemicellulase, trypsin, and papain. Among these, it is preferable to use one type selected from pectinase, protease, tannase and cellulase, or to use two or more types in combination. According to this, the extraction efficiency can be further improved. In addition, you may perform an enzyme process with respect to Amler fruit and Amler fruit juice.

  Further, in the above extraction, it is preferable to repeat the extraction step once or more for the extraction residue. According to this method, the extraction efficiency can be improved. The solvent used for extraction in this case may be the same or different.

  The above extract can be used as it is, but it is more preferable to remove the insoluble substances and the solvent by performing treatments such as filtration, centrifugation and fractional distillation. By performing such processing, the blood flow improvement effect is enhanced and the application range is widened.

  After removing the insoluble substances and the solvent, the fruit juice or the extract is directly or concentrated and then distributed using an organic solvent to obtain each solvent-soluble fraction. These solvent-soluble fractions are preferred because the blood flow improving effect is further enhanced. Examples of the organic solvent include lower alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, and butyl alcohol, ethyl acetate, butyl acetate, diethyl ether, methyl ether, methyl isobutyl ketone, hexane, acetone, and chloroform. Can be used. Further, in order to increase the purity of the soluble fraction, partitioning with other hydrophobic solvents can be combined, but in this case, the use of ethyl alcohol is preferred. The concentration of these solvents is not particularly limited, but from the viewpoint of yield and effect, the final concentration is preferably 20% to 80% (v / v), and 20% to 60% (v / v). Further preferred.

  In order to further increase the purity, for example, purification by chromatography or column using a hydrophobic resin based on phenol, styrene, acrylic acid, epoxyamine, pyridine, methacryl or the like may be performed. . In that case, as an eluent after resin adsorption, for example, lower alcohols such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, butyl alcohol, and acetone can be used alone or as an aqueous solution.

  The extract and fraction can be used as they are, but if necessary, they can be used after being dried and powdered by means such as spray drying or freeze drying.

  The composition for improving blood flow in the present invention can be used for the purpose of alleviating, improving or preventing blood circulation disorders. Examples of symptoms or diseases related to the blood circulation disorder include Raynaud's phenomenon, Raynaud's disease, Raynaud's syndrome, itching of the skin, fatigue, malaise, hyperlipidemia, arteriosclerosis, myocardial infarction, cerebral infarction, hyperemia, congestion. , Bleeding, anemia, dark redness around the skin, mucous membranes, nails, lips, eyes, etc., itchy skin, bleeding tendency, easy bruising, dizziness, hot flashes, bloody blood (nosebleed), hemoptysis, vomiting, melena, Examples thereof include hematuria, muscle pain, nausea, gastric sensation, and blood flow disorder observed in insomnia. It has been clarified that blood flow reduction is observed in the symptoms or diseases listed here, and a desired effect can be expected by improving the blood flow with the composition for improving blood flow of the present invention. Specific examples of fatigue include stiff shoulders and low back pain, and also includes coldness as one aspect thereof.

  The composition for improving blood flow of the present invention can be widely applied to foods and drinks, feeds, quasi-drugs, pharmaceuticals, and the like, but is particularly preferably applied to foods and drinks that can be easily consumed by humans.

  The food / beverage products in the present invention are not particularly limited as long as they can be taken orally, such as solutions, suspensions, powders, solid moldings and the like. Specific examples of food and drink include, for example, instant noodles, retort foods, canned foods, microwave foods, instant soups and miso soups, freeze-dried foods, soft drinks, fruit juice drinks, vegetable drinks, soy milk drinks, coffee Beverages, tea beverages, powdered beverages, beverages such as concentrated beverages, nutritional beverages, alcoholic beverages, bread products such as bread, pasta, noodles, cake mixes, fried flour, bread crumbs, rice cakes, caramel, chewing gum, chocolate, cookies, Seasonings such as biscuits, cakes, pies, snacks, crackers, Japanese confectionery, dessert confectionery, sauces, tomato processed seasonings, flavor seasonings, cooking mixes, sauces, dressings, soups, curry stew , Processed fats and oils, butter, margarine, mayonnaise and other fats, milk beverages, yogurts, lactic acid bacteria beverages, ice cream Milk products, creams and other dairy products, frozen foods, processed fish products such as fish ham and sausages, fish paste products, livestock processed products such as livestock ham and sausages, canned agricultural products, jams and marmalades, pickles, boiled beans, cereals And other processed agricultural products, nutritional foods, tablets, capsules and the like.

  The intake amount of the composition for improving blood flow of the present invention as a food or drink should be adjusted according to the disease state of the present invention, the body weight, age, constitution, physical condition, etc. of the sick person. The composition for improvement can be appropriately set in the range of 0.05 g to 20 g, preferably 0.1 g to 5 g. The above-mentioned food and drink can be taken in one to several times a day depending on the state of illness or food.

  In the present invention, various nutritional components can be strengthened when processed into a composition for improving blood flow or a food or drink containing the composition.

Nutritional ingredients that can be enhanced include vitamins such as vitamin A, vitamin B ₁ , vitamin B ₂ , vitamin B ₆ , vitamin B ₁₂ , vitamin C, vitamin D, vitamin E, niacin (nicotinic acid), pantothenic acid, folic acid, Essential amino acids such as lysine, threonine, tryptophan, minerals such as calcium, magnesium, iron, zinc, copper, and, for example, α-linolenic acid, EPA, DHA, evening primrose oil, octacosanol, casein phosphopeptide (CPP) , Casein calcium peptide (CCP), water-soluble dietary fiber, insoluble dietary fiber, substances that contribute to human health such as oligosaccharides, and other useful substances approved as foods and food additives The above can be used.

  The feed in the present invention refers to food for feeding to organisms other than humans, and the form thereof is not particularly limited. The organism to which the feed can be applied is not particularly limited, and examples thereof include farm animals and pet animals. Examples of farmed animals include domestic animals such as horses, cows, bras, sheep, goats, camels and llamas, laboratory animals such as mice, rats, guinea pigs and rabbits, and poultry such as chickens, ducks, turkeys and ostriches. is there. Examples of pet animals include dogs and cats.

  The quasi-drugs and pharmaceuticals in the present invention refer to those prepared as oral preparations or injections according to conventional methods using excipients and other additives suitable for oral or parenteral administration. Preferred quasi-drug and pharmaceutical embodiments are oral formulations, most preferred are oral solid formulations. This is because oral solid preparations can be easily taken and are convenient to store and carry.

  Examples of oral solid preparations include tablets, powders, fine granules, granules, capsules, pills, sustained release agents and the like. The oral solid preparation of the present invention comprises an appropriate pharmacologically acceptable carrier, excipient (eg starch, lactose, sucrose, calcium carbonate, calcium phosphate etc.), binder (eg starch, gum arabic, carboxymethylcellulose, Hydroxypropylcellulose, crystalline cellulose, alginic acid, gelatin, polyvinylpyrrolidone, etc.), lubricants (eg, stearic acid, magnesium stearate, calcium stearate, etc.), disintegrating agents (eg, carboxymethylcellulose, talc, etc.), etc. for improving blood flow It is obtained by mixing with a composition and solidifying.

  In addition, oral liquid preparations include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, etc., and generally used inert diluents such as purified water, The thing containing ethyl alcohol. The oral liquid preparation of the present invention further contains adjuvants such as wetting agents and suspending agents, sweeteners, flavors, fragrances, preservatives and the like in addition to the blood flow improving composition and diluent. May be.

  Injections suitable for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, emulsions and the like. Examples of the aqueous solution and suspension diluent include distilled water for injection and physiological saline. Examples of diluents for water-insoluble solutions and suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethyl alcohol, polysorbate 80, and the like. The injection may further contain adjuvants such as preservatives, wetting agents, emulsifiers, dispersants, stabilizers (for example, lactose), and solubilizing agents (for example, glutamic acid and aspartic acid). These are sterilized, for example, by filtration through a bacteria storage filter, blending with a bactericide or irradiation. These can also be used by producing a sterile solid composition and dissolving it in sterile water or a sterile solvent for injection before use.

  The dosage of the composition for improving blood flow of the present invention as a pharmaceutical is appropriately determined according to individual cases in consideration of the administration route, disease symptoms, age of the administration subject, sex, etc. The active ingredient per person is about 40 mg / day to 3 g / day, preferably 100 mg / day to 500 mg / day.

  EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, a following example does not limit the scope of the present invention.

[Example 1] Preparation of composition for improving blood flow 1
The dried Amler fruit was crushed and sieved to 40 mesh or less, 2 L of distilled water was added to 80 g of the powder, and extraction was performed at 55 ° C. for 3 hours. Thereafter, the extract was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the extract and the residue were separated. 2 L of distilled water was added to the residue, extraction was repeated once more under the same conditions, and the extracts were combined and then lyophilized to obtain 35.0 g of composition A for improving blood flow of the present invention. . The yield was 43.8%.

[Example 2] Preparation of composition for improving blood flow 2
The dried Amler fruit was crushed and sieved to 40 mesh or less, 2 L of distilled water was added to 100 g of the powder, 0.1 g of pectinase and 0.1 g of tannase were added, and extraction was performed at 55 ° C. for 2 hours. Thereafter, the enzyme was inactivated at 90 ° C. for 30 minutes. Thereafter, the enzyme-treated solution was centrifuged (3000 rpm, 10 minutes), the supernatant was filtered, and the filtrate was further spray-dried to obtain 45 g of the composition B for improving blood flow of the present invention.

[Test Example 1] Confirmation of blood flow improvement effect 1
Here, in order to confirm the blood flow improvement effect of the composition for improving blood flow of the present invention, the change in blood flow velocity (μL / sec) when the composition for improving blood flow was added to human blood was investigated. .

  (1) Blood collection method and test method

  Using a vacuum blood collection tube (manufactured by Terumo Corp .: treated with heparin sodium), blood was collected from the mesenteric vein of a healthy subject in a sitting position at rest. The obtained blood (test blood) was dispensed 1 mL at a time, and 4 μL each of a solution prepared by adjusting the blood flow improving composition A of Example 1 with a physiological saline solvent to a final concentration of 20 μg / mL was added. In addition, it used for the measurement. On the other hand, as a control blood (control), a solution to which 4 μL of physiological saline as a solvent was added was prepared and subjected to measurement in the same manner.

  In addition, a test group in which 4 μg / mL of lipopolysaccharide (hereinafter referred to as LPS) that induces thrombus was added to the test blood and a test group in which the same amount of LPS was added to the control blood were set, and these were also measured. It was used for.

  (2) Measurement of blood flow velocity

  The blood flow velocity was measured using MC-FAN (manufactured by Hitachi Haramachi Electronics Co., Ltd.). In addition, as a microfabricated flow path of a blood vessel model for allowing blood to pass, 8736 parallel grooves forming a fine groove having a flow path depth of 4.5 μm, a flow path width of 7 μm at the center of the depth, and a flow path length of 30 μm. A silicon single crystal substrate on which a microchannel array is arranged (Bloody 6-7; manufactured by Hitachi Haramachi Electronics Co., Ltd.) was used. And 100 microliters of blood was poured by 20 cm water column difference, and the whole blood passage time was measured as blood flow passage time. At the same time, the state of blood flow was recorded with a microscope-video camera system. As the measurement values, the average value of all three measurements was used. The obtained blood flow passage time was corrected by setting the time required for 100 μL of physiological saline to pass through to 12 seconds. Based on this correction value, the blood flow velocity (μL / second) was obtained by calculation. The results are shown in Table 1.

  (3) Results and discussion

In the control in which the composition A for improving blood flow of the present invention was not added, the blood flow velocity was 1.52 μL / second, whereas in the test group to which the composition A for improving blood flow of the present invention was added, The flow rate was 1.97 μL / sec. That is, since the blood flow velocity was increased by the addition of the composition A for improving blood flow of the present invention, the existence of the blood flow improving effect was proved. Moreover, in the two test groups to which LPS for inducing thrombus was added, the blood flow velocity was slower than that of the control. However, in the test group to which the composition A for improving blood flow of the present invention was added, the blood flow velocity was about 10 times faster than in the test group that was not. This means that the composition A for improving blood flow of the present invention has an effect of improving blood flow in a state where thrombi are easily formed. Incidentally, when the same test was performed using the composition B for improving blood flow of Example 2 described above, the same result was obtained.

[Test Example 2] Confirmation of blood flow improvement effect 2
Again, in order to confirm the blood flow improvement effect of the composition for improving blood flow of the present invention, the change in blood flow velocity (μL / sec) when the composition for improving blood flow was added to human blood was investigated. .

  (1) Blood collection method

  Using a vacuum blood collection tube (manufactured by Terumo Corp .: treated with heparin sodium), blood was collected from the mesenteric vein of a healthy subject in a sitting position at rest. The obtained blood (test blood) was dispensed 1 mL at a time, and the composition A for improving blood flow of Example 1 was used as a physiological saline solvent so that the final concentrations were 2 ng / mL, 4 ng / mL, and 10 ng / mL. 4 μL of each of the solutions prepared in (1) was added to the measurement. On the other hand, as a control blood (control), a solution to which 4 μL of physiological saline as a solvent was added was prepared and subjected to measurement in the same manner.

  (2) Measurement of blood flow velocity

  The blood flow passage time was measured according to the method of Test Example 1, and the blood flow velocity (μL / second) was obtained based on the correction value of the blood flow passage time. The results are shown in Table 2.

  (3) Results and discussion

In the control to which the composition A for improving blood flow of the present invention was not added, the blood flow velocity was 1.58 μL / second, whereas in the test group to which the composition A for improving blood flow of the present invention was added, The flow rates were 1.89 μL / sec, 2.08 μL / sec, and 2.42 μL / sec, respectively. That is, the addition of the composition A for improving blood flow according to the present invention increases the blood flow velocity in a concentration-dependent manner, demonstrating the existence of a blood flow improving effect.

[Test Example 3] Confirmation of blood flow improvement effect 3
Here, in order to confirm the blood flow improvement effect of the composition for improving blood flow of the present invention, the change in blood flow rate (μL / sec) in humans before and after the intake of the composition for improving blood flow was investigated.

  (1) Subject

  Four healthy men were selected as subjects.

  (2) Method of ingesting and collecting blood flow improving composition

  Each subject was orally ingested 3 g of the composition A for improving blood flow of Example 1, and blood was collected 2, 4, 6 and 8 hours after ingestion. Blood collection was performed using a vacuum blood collection tube (manufactured by Terumo Co., Ltd .: heparin sodium treatment) from the medial cubital vein at the sitting position in a resting state. The obtained blood (test blood) was immediately used for measurement of blood flow velocity. In addition, for the control of the intake test, each subject collected blood without having breakfast on the day of the test. In addition, the test was performed by drinking 150 mL of tap water simultaneously with the intake of the composition A for improving blood flow. The measurement results of blood flow velocity are shown in Table 3.

  (3) Results and discussion

By ingesting the composition A for improving blood flow of the present invention, the blood flow velocity was increased in a time-dependent manner in any subject, and the existence of the blood flow improving effect was demonstrated. It was also found that the effect was maintained even when 8 hours had passed after ingestion.

[Test Example 4] Confirmation of blood flow improvement effect 4
Again, in order to confirm the blood flow improving effect of the composition for improving blood flow of the present invention, the change in blood flow velocity (μL / sec) in humans before and after the intake of the composition for improving blood flow was investigated.

  (1) Subject

  Six healthy men and women (3 men and 3 women) were selected as subjects.

  (2) Method of ingesting and collecting blood flow improving composition

  Each subject was orally ingested 3 g of composition B for improving blood flow of Example 2, and blood was collected 3 hours after ingestion. Blood collection was performed using a vacuum blood collection tube (manufactured by Terumo Co., Ltd .: heparin sodium treatment) from the medial cubital vein at the sitting position in a resting state. The obtained blood (test blood) was immediately used for measurement of blood flow velocity. In addition, for the control of the intake test, each subject collected blood without having breakfast on the day of the test. In addition, the test was performed by drinking 150 mL of tap water simultaneously with the intake of the composition B for improving blood flow. Table 4 shows the measurement results of blood flow velocity.

  (3) Results and discussion

By ingesting the composition B for improving blood flow of the present invention, the blood flow velocity was increased in any subject, and the existence of the blood flow improving effect was demonstrated. The effect was confirmed in both men and women.

[Example 3] Preparation of food / beverage product (tablet confectionery) containing a composition for improving blood flow The composition A for blood flow obtained in Example 1, 5 g, 30 g of lactose, DHA-containing powdered oil (Suncoat DY-5) Manufactured by Taiyo Kagaku Co., Ltd.) 12 g, sucrose fatty acid ester 4 g, and yoghurt flavor 4 g are mixed, and this mixture is pressure-molded using a rotary tableting machine, and one tablet is 300 mg for improving blood flow A composition-containing food or drink (tablet cake) was obtained. In addition, as a comparative example for this, a food or drink (tablet cake) containing other components such as lactose was obtained by the same method, while not containing only the composition for improving blood flow.

  And as a result of performing a sensory test by these five kinds of tablet confectionery by five panelists, no significant difference was recognized in both color, smell and taste. In addition, when these two types of tablet confectionery were stored at room temperature for a long time (1 month, 3 months, 6 months), neither of them showed any noticeable changes in color, smell or taste, and both were stored. It was excellent in nature.

[Example 4] Preparation of food / beverage product containing beverage for improving blood flow (beverage) Composition A for blood flow obtained in Example 1, 5 g, 2.1 g of 1/5 concentrated grapefruit transparent fruit juice, 30 g of erythritol, 2.5 g of citric acid crystals, 0.5 g of trisodium citrate, 0.5 g of L-ascorbic acid, 1.93 g of calcium lactate, 0.15 g of CCP, and grapefruit flavor 1.0 were mixed and dissolved in water to make a total volume of 1000 mL. . After filling it into a 100 mL bottle and sealing with a cap, it was sterilized by heating at 90 ° C. for 30 minutes to obtain a food / beverage product (beverage) containing the composition for improving blood flow of the present invention. Moreover, as a comparative example to this, although not containing only the composition A for improving blood flow, a food or drink (beverage) containing other components was obtained by the same method.

  And as a result of performing a sensory test by these five kinds of beverages with respect to these two kinds of beverages, no significant difference was observed in any of color, smell and taste. In addition, when these two types of beverages were stored in a refrigerator for a long time (1 month, 3 months, 6 months), no significant changes were observed in color, smell, and taste in either of them, and all of them were preserved. It was excellent.

[Example 5] Preparation of food / beverage product containing a composition for improving blood flow (vegetable juice mixed drink) Composition A for blood flow improvement obtained in Example 1, 0.2 g, guar gum decomposition product (Sunfiber R; Sun 3 g of Chemical Co., Ltd.) was added to, mixed and dissolved in 100 mL of a commercially available vegetable juice mixed beverage to obtain a composition-containing food or drink (vegetable juice mixed beverage) for improving blood flow of the present invention. Moreover, the food / beverage products (vegetable juice mixed drink) which do not contain the composition A for blood flow improvement but contain a guar gum decomposition product as a comparative example with respect to this were obtained by the same method.

  And as a result of performing the sensory test by these five kinds of vegetable juice mixed drinks by five panelists, no significant difference was recognized in any of color, smell and taste. In addition, when these two types of beverages were stored in a refrigerator for one month, no noticeable changes in color, smell, and taste were observed in either of them, and all were excellent in storage stability.

[Example 6] Preparation of food and drink (cookie) containing composition for improving blood flow After putting 4 g of composition A for improving blood flow obtained in Example 1 and 200 g of commercially available cake mix powder into a container, butter 35 g was added and mixed with wooden coconut. 25g of beaten egg was added to it and kneaded well until it became a smooth dough. The dough is taken out on a table on which the flour has been shaken, and further, the flour is shaken and stretched to a thickness of 5 mm with a rolling pin, extracted in a round shape, and baked in an oven at 170 ° C. for 10 minutes. Obtained a food / beverage product (cookie) containing the composition for improving blood flow.

[Example 7] Preparation of food / beverage product containing blood flow improving composition (yogurt) 1 g of blood flow improving composition A obtained in Example 1, commercially available skim milk (manufactured by Meiji Dairies, protein content 34% ) 95 g and 35 g of commercially available unsalted butter (manufactured by Snow Brand Milk Products Co., Ltd.) were dissolved in 0.8 L of warm water, homogenized, and the total amount was adjusted to 1 L. Next, this was heat sterilized at 90 ° C. for 15 minutes, cooled, and inoculated with 3 g of commercially available lactic acid bacteria starter (manufactured by Hansen) (2 g of Streptococcus thermophilus and 1 g of Lactobacillus bulgaricus). Furthermore, this is mixed uniformly, dispensed and filled into a 100 mL container, sealed, fermented at 37 ° C. for 20 hours, and then cooled, thereby containing the composition for improving blood flow of the present invention. (Yogurt) was obtained.

[Example 8] Preparation of food / beverage product (oral liquid food) containing a composition for improving blood flow 50 g sodium caseinate (DMV), 42.5 g egg white enzyme degradation product (Taiyo Kagaku), dextrin (Matsuya Chemical) ) 100 g was dissolved in 1 L of water and the aqueous phase was prepared in a tank. Separately, 45 g of MCT (manufactured by Kao Corporation), 17.5 g of palm oil (manufactured by Fuji Oil Co., Ltd.), 35 g of safflower oil (manufactured by Taiyo Oil & Fats Co., Ltd.), 0.7 g of lecithin (manufactured by Taiyo Kagaku Co., Ltd.), defoaming 1 g of an agent (manufactured by Taiyo Chemical Co., Ltd.) was mixed and dissolved to prepare an oil phase. The oil phase was added to the aqueous phase in the tank, stirred and mixed, then heated to 70 ° C., and further homogenized with a homogenizer at a pressure of 14.7 MPa. Next, the mixture was sterilized at 90 ° C. for 10 minutes, then concentrated and spray-dried to prepare about 260 g of an intermediate product powder. 200 g of this intermediate product powder, composition A for blood flow improvement obtained in Example 1, 4 g, 156 g of dextrin (manufactured by Matsutani Chemical Co., Ltd.), 18 g of guar gum decomposition product (Sunfiber R; manufactured by Taiyo Chemical Co., Ltd.), a small amount Vitamins and minerals and powdered flavor were added and mixed uniformly to obtain about 380 g of food and drink (oral liquid food) containing the composition A for improving blood flow.

[Example 9] Preparation of tablet containing composition for improving blood flow A, 10 g of composition A for improving blood flow obtained in Example 1, 5 g of crystalline cellulose, 13.8 g of corn starch, 32.5 g of lactose, hydroxypropylcellulose 3.3 g was mixed and granulated. To this granulated product, 1.0 g of magnesium stearate is added, mixed uniformly, and this mixture is pressure-molded with a rotary tableting machine, whereby one tablet contains 130 mg of the composition for improving blood flow of the present invention. Got.

[Example 10] Preparation of a drink containing a composition for improving blood flow Into 55 g of the composition A for improving blood flow obtained in Example 1, 528 g of glucose, 85.4 g of fructose, 15.8 g of powdered citric acid, and citrus Sodium 11.2 g, calcium lactate 1.3 g, magnesium chloride 1.3 g, powdered natural flavoring 13.2 g, vitamin C were added, and water was added to make 11 liters. This liquid was filled in a dry heat sterilized 110 ml brown bottle, sealed with an aluminum cap, and then sterilized at 120 ° C. for 30 minutes to obtain 100 drinks.

Example 11 Preparation of Capsules Containing Composition for Improvement of Blood Flow After adding 50 g of composition A for improving blood flow obtained in Example 1 to 1 g of copper chlorophyllate and heat sterilizing it, The pharmacy capsule (# 1) was filled with 0.4 g per capsule to obtain 100 capsules.

[Example 12] Preparation of pig breeding feed containing composition for improving blood flow For 5 parts by weight of composition B for improving blood flow obtained in Example 2, 40.0 parts by weight of corn and 28.0 parts of milo Part by weight, 11.0 parts by weight of soybean oil residue, 6.0 parts by weight of bran, 5.0 parts by weight of fish meal, 2.0 parts by weight of animal fats and oils, and 3.0 parts by weight of vitamins and minerals 20 kg of breeding feed was prepared.

  Examples of the present invention and the target product are as follows.

  (1) A composition for improving blood flow comprising, as an active ingredient, at least one selected from the group consisting of Amler fruit, Amler fruit juice, Amler fruit extract and Amler fruit extract.

  (2) In the above (1), the extract is at least one selected from the group consisting of water, a base, an acid and a hydrophilic solvent. A composition for improving blood flow, characterized in that the composition is extracted by one.

  (3) The composition for improving blood flow according to (1), wherein the extract is obtained by extracting at least one raw material selected from the group consisting of Amler fruit and Amler fruit juice with water. .

  (4) In the above (2), the hydrophilic solvent is at least one lower alcohol selected from the group consisting of methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol and butyl alcohol. A composition for improving blood flow.

  (5) In said (1), while containing the fraction by the organic solvent of the said extract as said active ingredient, the said organic solvent is methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, butyl alcohol, A composition for improving blood flow, which is at least one selected from the group consisting of ethyl acetate, butyl acetate, diethyl ether, methyl ether, methyl isobutyl ketone, hexane and chloroform.

  (6) The composition for improving blood flow according to the above (1), comprising a fraction obtained by ethyl alcohol of the extract as the active ingredient.

  (7) A composition for improving blood flow according to the above (1), wherein a precipitate fraction component of ethyl acetate with the extract is contained as the active ingredient.

  (8) Blood characterized by containing, as the active ingredient, a soluble fraction obtained by fractionating the extract with 20% to 80% (v / v) ethyl alcohol in (1) above Flow improving composition.

  (9) Blood characterized by containing, as the active ingredient, a soluble fraction obtained by fractionating the extract with 20% to 60% (v / v) ethyl alcohol in (1) above Flow improving composition.

  (10) A composition for improving blood flow according to the above (1), which contains, as the active ingredient, a product obtained by purifying the extract by chromatography or column using a hydrophobic resin.

  (11) In (10) above, the hydrophobic resin is based on at least one resin selected from the group consisting of phenolic, styrene, acrylic acid, epoxyamine, pyridine and methacrylic. A composition for improving blood flow.

  (12) In the above (1), a fraction obtained by purifying a product obtained by treating and decomposing the extract with at least one enzyme selected from the group consisting of pectinase, protease, tannase and cellulase, A composition for improving blood flow, which is contained as the active ingredient.

  (13) A composition for improving blood flow, comprising Amler as an active ingredient.

  (14) A composition for improving blood flow, comprising an edible portion of Amler as an active ingredient.

  (15) A composition for improving blood flow, comprising a substance derived from Amler as an active ingredient.

  (16) A food or drink comprising the composition for improving blood flow according to any one of (1) to (15) above.

  (17) A feed comprising the composition for improving blood flow according to any one of (1) to (15) above.

  (18) A quasi-drug containing the composition for improving blood flow according to any one of (1) to (15) above.

  (19) A pharmaceutical comprising the composition for improving blood flow according to any one of (1) to (15) above.

  (20) Blood flow using a composition for improving blood flow containing, as an active ingredient, at least one selected from the group consisting of Amler fruit, Amler fruit juice, Amler fruit extract, and Amler fruit extract. Blood flow improvement method to improve sex.

  (21) A blood flow improving method for improving blood fluidity using a blood flow improving composition containing Amler as an active ingredient.

  (22) A blood flow improvement method for improving blood fluidity using a composition for improving blood flow containing an edible portion of Amler as an active ingredient.

  (23) A blood flow improving method for improving blood fluidity using a composition for improving blood flow containing an Amler-derived substance as an active ingredient.

  (24) In vivo using at least one selected from the group consisting of Amler fruit, Amler fruit juice, Amlar fruit extract and Amler fruit juice extract as an active ingredient A blood flow improvement method for improving blood fluidity.

  (25) let the organism ingest a composition for improving blood flow containing, as an active ingredient, at least one selected from the group consisting of Amler fruit, Amler fruit juice, Amler fruit extract and Amler fruit extract, A blood flow improvement method for improving blood fluidity in the living body.

  (26) An organism is orally ingested with a composition for improving blood flow, containing at least one selected from the group consisting of Amler fruit, Amler fruit juice, Amler fruit extract and Amler fruit juice extract as an active ingredient. The blood flow improvement method which improves the fluidity of blood in the living body.

  (27) The method for improving blood flow according to the above (25) or (26), wherein the organism is an organism other than a human being.

Claims (9)

  A composition for improving blood flow comprising, as an active ingredient, at least one selected from the group consisting of Amler fruit, Amler fruit juice, Amler fruit extract, and Amler fruit extract.   The composition for improving blood flow according to claim 1, wherein the extract is obtained by extracting at least one selected from the group consisting of Amler fruit and Amler juice with a non-organic solvent.   The composition for improving blood flow according to claim 1 or 2, wherein a fraction obtained by using an organic solvent of the extract is contained as the active ingredient.   The blood flow improvement according to any one of claims 1 to 3, wherein a fraction obtained by purifying a product obtained by decomposing the extract with an enzyme is purified as the active ingredient. Composition.   The composition for improving blood flow according to claim 4, wherein the enzyme is a hydrolase.   A food or drink comprising the composition for improving blood flow according to any one of claims 1 to 5.   A feed comprising the composition for improving blood flow according to any one of claims 1 to 5.   A quasi-drug containing the composition for improving blood flow according to any one of claims 1 to 5.   A pharmaceutical comprising the composition for improving blood flow according to any one of claims 1 to 5.